Last reviewed · How we verify
Off-site - methadone or no agonist — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Off-site - methadone or no agonist (Off-site - methadone or no agonist) — Ruth M. Rothstein CORE Center.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Off-site - methadone or no agonist TARGET | Off-site - methadone or no agonist | Ruth M. Rothstein CORE Center | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Off-site - methadone or no agonist CI watch — RSS
- Off-site - methadone or no agonist CI watch — Atom
- Off-site - methadone or no agonist CI watch — JSON
- Off-site - methadone or no agonist alone — RSS
Cite this brief
Drug Landscape (2026). Off-site - methadone or no agonist — Competitive Intelligence Brief. https://druglandscape.com/ci/off-site-methadone-or-no-agonist. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab